Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

147

Enrollment

NIH

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DRUG: Gilteritinib
DRUG: Venetoclax

Sponsor

National Cancer Institute (NCI)